



Civil society briefing

WHO TB Vaccine Accelerator

Finance and Access Working Group for novel TB vaccines

25 February 2026

01

Opening remarks and welcome

Meeting Chair



Mike Frick

Co-Director, Tuberculosis project,
Treatment Action Group



Member of TB Vaccine Accelerator
Finance & Access Working Group

Agenda

Opening remarks and welcome	14.00 – 14.15
• Opening remarks & agenda (<i>Chair</i>)	<i>5 mins</i>
• Welcome from WHO (<i>WHO</i>)	<i>10 mins</i>
Report presentation	14.15 – 14.40
• Presentation on F&A WG 2025 report & 2026 plans (<i>WHO</i>)	<i>20 mins</i>
• Remarks from co-convenors (<i>Gavi & South Africa</i>)	<i>5 mins</i>
Discussion	14:40 – 15:25
• Q&A and civil society perspectives (<i>All, moderated by Chair</i>)	<i>45 mins</i>
Closing	15:25 – 15:30

Welcome from WHO

02

Report presentation

In 2023, WHO launched the TB Vaccine Accelerator Council

Aims to support the community of key stakeholders accelerate the development, approval and use effective novel TB vaccines, as part of the basket of interventions to combat TB



In 2024, commitment to convene stakeholders in 2025 to discuss **options for procurement and financing of late-stage vaccines**

In 2025, WHO launched the global Finance & Access Working Group

Co-convened by **WHO, Gavi and the Government of South Africa**

2. Establishment of the finance and access working group

In May 2024, Members of the Council requested the WHO Secretariat to establish working groups to accelerate the achievement of goals aligned to its mission. Four working groups will be established in a phased approach: vaccine research, and innovation; product development, policy & manufacturing; finance & access; and country readiness, advocacy, & community partnership.

The finance and access working group was established in February 2025.

In February 2025, the TB Accelerator launched the [Finance and Access Working Group](#) with the goal of ensuring timely, equitable, and sustainably financed access to affordably priced new TB vaccines in all countries with demand based on public health needs. The Working Group held its **first meeting on 14 February 2025** and will continue to meet monthly thereafter. It is co-convened by South Africa, WHO, and Gavi, each bringing distinct expertise in vaccine financing and access. Members include representatives of governments, health and development partners, financing institutions, academia, and civil society.

Progress update reports



[Progress update report of the TB Vaccine Accelerator Council: November 2024-February 2025](#)



[Progress update report of the TB Vaccine Accelerator Council: March 2025 - December 2025](#)

Finance and Access Working Group: Vision and Terms of Reference

Vision:

To promote timely, equitable and sustainably financed access to affordably priced new TB vaccines in all countries, driven by public health need, fostering sustainable supply

Goals



2025

- Develop an **early understanding** of anticipated barriers, bottlenecks, challenges and supply-demand dynamics relevant to country financing and access for novel TB vaccines
- Accelerate the identification of financing and access **solutions and opportunities** to incentivize equitable and affordable global access
- Develop a **financing and access options framework**, outlining mechanisms that enable countries to have timely and sustainable access to novel TB vaccines
- Coordinate efforts across governments, partners, financing institutions, private sector, and civil society to **propose strategic partnerships and financing and access mechanisms** with global applicability, while maintaining a particular focus on speeding up vaccine availability and access for high TB-burden countries

2026 +

- Foster the **design, development and implementation** of financing and access solutions that enable countries to have timely and sustainable access to safe, effective, and affordably priced TB vaccines.

Finance and Access Working Group Members List

Co-conveners



Norbert Ndjeka
Chief Director – TB Control and Management,
National Department of Health



Dominic Hein
Director – Market Shaping, Gavi, the Vaccine
Alliance



Tara Lavanya Prasad
Team Lead – Vaccine Access & Decision Making,
Immunization, Vaccines and Biologicals
department, WHO

Observers



Gian Gandhi
Deputy Director, Vaccine Access, Gates
Foundation



Antonia Lombardi
Senior Policy Officer, Wellcome Trust

Permanent members



Lindiwe Mvusi
Director – TB Control and Management,
National Department of Health



Marion Menozzi-Arnaud
Head, Market Shaping, Futures Programmes and
Vaccine Innovations, Gavi, the Vaccine Alliance



Santiago Cornejo
Executive Director, Revolving Fund for Access to Vaccines, Pan
American Health Organization
(alternate: Murat Ozturk, Supply Chain Advisor)



Dinesh Arora
Principal Health Specialist, Asia Development Bank



Cristina Niculescu
Life Science Investment Specialist, EIB
(alternate: Valeria Iansante, Life Science Specialist)



Nicolas (Nick) Menzies
Associate Professor of Global Health, Harvard TH Chan School
of Public Health



Richard White
Professor of Infectious Disease Modelling, London School of
Hygiene and Tropical Medicine



Mike Frick
Co-Director, Tuberculosis project, Treatment Action Group



Andrew Jones
Deputy Director, UNICEF Supply Division Vaccine Centre
(alternate: Kristina Lorensen, Senior Contract Manager)



Eliud Wandwalo
Head, TB, Global Fund to Fight AIDS, TB and Malaria
(alternate: Grania Brigden, Senior TB Advisor)



Frauke Uekermann
Director, Vaccine Markets, Clinton Health Access Initiative
(alternate: Verena Damovsky, Clinton Health Access Initiative)



Abebe Genetu Bayih
Ag. Lead Local Manufacturing of Health Commodities, Africa
Centres for Disease Control and Prevention



Erlina Burhan
Pulmonologist, Head of TB Expert, Coalition Against TB
Faculty of Medicine, Universitas Indonesia – Persahabatan
Hospital



Dauda Foday Suma
Principal Industrial/Manufacturing Development Officer,
Africa Development Bank



Éder Gatti
Director, National Immunization Program
(alternate: Fernanda Dockhorn, General Coordinator, TB)



Ana Liza Hombrado Duran
Director, Research Institute for Tropical Medicine



Bonanza Perwira Taihitu
Senior Advisor to Minister of Health, Politics and Global Health
(alternate: Wenny Indriasari, Technical Official MoH)



Guy Pickles
Head of Vaccines, MedAccess
*(alternate: Gillian Leitch, Head, HIV, TB and Antimicrobial
Resistance)*

Civil society focused engagement in F&A: 2025 to date

28th May 2025

Civil Society Information Session:
Finance and Access Working
Group of the WHO TB Vaccine
Accelerator Council

28 May 2025 14:00 – 15:00 CET



Civil Society Information Session:

Finance and Access Working Group of the WHO TB Vaccine Accelerator Council

When: 28 May 2025, 14:00H – 15:00H CEST

[Civil Society Information Session: Finance and Access Working Group of the WHO TB Vaccine Accelerator Council](#)

22nd Sep 2025

Landscape and evidence
to date: Public Summary
for Consultation

Catalysing solutions for
equitable global access and
sustainable financing for
novel tuberculosis vaccines
for adults and adolescents:
Landscape and evidence to date

SEPTEMBER 2025

Shared with over
450 civil society
members

Feedback received on: Ideas on
solutions, clarifications, facts,
methodologies, assumptions

25th February 2026

Today's Civil Society
Information Session – to brief
on the F&A report

Civil Society Information Session

**WHO TB VACCINE ACCELERATOR
GLOBAL FINANCE AND ACCESS
WORKING GROUP
FOR NOVEL TB VACCINES**

The World Health Organization (WHO) is organizing a special information-sharing webinar to update Civil Society and TB-affected communities on the vision and activities of the Global Finance and Access Working Group of the WHO TB Vaccine Accelerator Council.


Co-convened by WHO, the Government of South Africa, and Gavi – the Finance and Access Working Group recently released a [new report](#) that presents a first-of-its-kind analysis of the anticipated barriers, bottlenecks, and market dynamics that could impact timely, equitable, and sustainable access to novel TB vaccines. The report sets out the Working Group's shared vision for equitable access to novel TB vaccines and identifies six urgently needed solutions to accelerate access and financing and highlights the roles of different stakeholders to support the implementation of these solutions.

On 6th November 2025, WHO published:

'Catalyzing solutions for equitable global access and sustainable financing for novel tuberculosis vaccines for adults and adolescents'

This report:

- Sets out the **F&A Working Group's shared vision** for equitable access to novel TB vaccines
- Advances a **shared understanding of the current landscape and its possible evolution** in the future.
- Is a **first-of-its-kind analysis** of the anticipated barriers, bottlenecks, and market dynamics that could impact timely, equitable, and sustainable access to novel TB vaccines on the horizon.
- **Highlights six urgently needed solutions and priority actions** for governments, health partners, funders, suppliers and civil society to accelerate equitable access to novel TB vaccines.



DOWNLOAD THE REPORT HERE: [Catalyzing solutions for equitable global access and sustainable financing for novel tuberculosis vaccines for adults and adolescents](#)

READ THE WHO NEWS RELEASE HERE: [New WHO report urges bold steps for equitable access to novel TB vaccines](#)

Acknowledgements

Non-exhaustive

Finance & Access Working Group

Co-conveners	Permanent members
<p>Norbert Ndjeka Chief Director – TB Control and Management, National Department of Health</p> <p>Lindive Mvusi Director – TB Control and Management, National Department of Health</p> <p>Dominic Hein Director – Market Shaping, Gavi, the Vaccine Alliance</p> <p>Marion Menozzi-Arnaud Senior Specialist – Market Shaping, Gavi, the Vaccine Alliance</p> <p>Tara Lavanya Prasad Team Lead – Vaccine Access, Department of Immunization, Vaccines and Biologicals, WHO</p> <p>Matteo Zignol Unit Head – Prevention, Diagnosis, Treatment, Care & Innovation, Global Programme on Tuberculosis and Lung Health, WHO</p>	<p>Santiago Cornejo Executive Director, Revolving Fund for Access to Vaccines, Pan American Health Organization <i>(alternate: Murat Ozturk, Supply Chain Advisor)</i></p> <p>Dinesh Arora Principal Health Specialist, Asia Development Bank</p> <p>Cristina Niculesc Life Science Investment Specialist, EIB <i>(alternate: Valeria Iannone, Life Science Specialist)</i></p> <p>Nicolas (Nick) Menzies Associate Professor of Global Health, Harvard TH Chan School of Public Health</p> <p>Richard White Professor of Infectious Disease Modelling, London School of Hygiene and Tropical Medicine</p> <p>Mike Frick Co-Director, Tuberculosis project, Treatment Action Group</p> <p>Andrew Jones Deputy Director, UNICEF Supply Division Vaccine Centre <i>(alternate: Kristina Lorensen, Senior Contract Manager)</i></p> <p>Eliud Wandwalo Head, TB, Global Fund to Fight AIDS, TB and Malaria <i>(alternate: Grania Bridgen, Senior TB Advisor)</i></p> <p>Frauke Uskermann Director, Vaccine Markets, Clinton Health Access Initiative <i>(alternate: Verena Damovsky, Clinton Health Access Initiative)</i></p> <p>Abebe Genetu Bayih Ag. Lead Local Manufacturing of Health Commodities, Africa Centres for Disease Control and Prevention</p> <p>Erlina Burhan Pulmonologist, Head of TB Expert, Coalition Against TB Faculty of Medicine, Universitas Indonesia – <i>Persahabatan</i> Hospital</p> <p>Dauda Foday Suma Principal Industrial/Manufacturing Development Officer, Africa Development Bank</p> <p>Éder Gatti Director, National Immunization Program</p> <p>Ana Liza Hombrado Duran Director, Research Institute for Tropical Medicine</p> <p>Bonanza Perwira Taihtu Senior Advisor to Minister of Health, Politics and Global Health</p> <p>Guy Pickles Head of Vaccines, MedAccess <i>(alternate: Gillian Leitch, Head, HIV, TB and Antimicrobial Resistance)</i></p>

Civil Society organizations and individuals

WHO Civil Society Task Force on Tuberculosis

<p>Ms Ashra Aghesh</p>	<p>Ms Yulia Kalanche</p>	<p>Dr Yassen Tcholakov</p>
<p>Ms Handas Enkh-Amgalan</p>	<p>Dr Karina Kistmann</p>	<p>Dr Helene Mari Van Der Westhuizen</p>
<p>Dr Abrarul Islam</p>	<p>Dr Ghulam Qader Qader</p>	<p>Mr Luan Yu</p>
<p>Ms Victoria James</p>	<p>Ms Ida Savadogo Yagbare</p>	<p>Mr Timothy Wafuta</p>

WHO TB Vaccine Accelerator Leadership & Secretariat

Support to WHO

Gates Foundation



Accenture Development Partnerships



TB Vaccine Accelerator Council

Members of the Ministerial Board	Members of the Principal Group
<p>Dr Nisha Trindade Lima (Co-chair) Minister of Health, Brazil</p> <p>Dr Budi Gunadi Sukidin (Co-chair) Minister of Health, Indonesia</p> <p>Mr Aurélien Bouteaux Minister of Social Affairs and Health, France</p> <p>Dr Debash Mungai Mutitu Global Director for Health, Kenya</p> <p>Ms Doo Hing Lam Minister of Health, Viet Nam</p> <p>Dr Malik Waqar Ahmad Bhurath Executive Director for Health, Pakistan</p> <p>Dr Aaron Motsoaledi Minister of Health, South Africa</p> <p>Dr Theodore J. Berenson Secretary of Health, Philippines</p> <p>National Institutes of Health National Institutes of Health, United States of America</p>	<p>Dr Abimoumi Adema President, African Development Bank Group</p> <p>Dr Trevor Mbeke President of Global Health, Bill and Melinda Gates Foundation</p> <p>Ms Nadia Calviño President, European Investment Bank</p> <p>Dr Juan Pablo Uribe Global Director for Health, Nutrition & Population and the Global Financing Facility, World Bank</p> <p>Dr Sanna Nishkar Chief Executive Officer, GAVI, the Vaccine Alliance</p> <p>Mr Peter Sands Executive Director, Global Fund</p> <p>Dr Philippe Duneton Executive Director, UNICEF</p> <p>Dr John-Arne Rattigan Chief Executive Officer, Wellcome Trust</p> <p>Dr Lucian Oltar Executive Director, Stop TB Partnership</p> <p>Mike Frick Co-Director of Tuberculosis Project, Treatment Action Group</p>

Supply Stakeholders

WHO Regional Offices TB and Immunization Advisors



Together for a TB-free world: Financing and access solutions for novel TB vaccines



About the Event

The Government of South Africa and the World Health Organization (WHO) are co-organizing a high-level side event: "Together for a TB-free world: Financing and access solutions for novel TB vaccines," on the sidelines of the G20 Health Ministers' Meeting.

The objective of the side event is to foster inclusive dialogue and collaboration across sectors and geographies to promote sustainable TB vaccine supply and equitable access to safe, effective and affordably priced TB vaccines, particularly in high-burden countries, as rapidly as possible.

The WHO report, "Catalysing solutions for equitable global access for sustainable financing for novel tuberculosis vaccines for adults and adolescents," will be launched at the event.

Panellists will include ministers of health, particularly from high-burden countries, and leaders from key global and regional partner institutions, as well as representatives of civil society.



Participation in the event is by invitation only

6 November 2025 | 10:00 AM – 12:00 PM (South Africa time +1hr from Geneva)

G20 Health Ministers Meeting, Polokwane, Limpopo, South Africa

The report was launched at the G20 Health Minister's meeting in South Africa

Session: 'Together for a TB-free world: Financing and access solutions for novel tuberculosis vaccines', co-hosted by Govt. of South Africa & WHO

(G20 Health Minister's meeting | 6 November 2025 | Limpopo, South Africa)

WHO Assistant Director-General **Dr Jeremy Farrar** and **Minister of Health of South Africa Dr Aaron Motaledi** joined G20 health ministers, TB Vaccine Accelerator Council members, leaders of international organizations, health partners, funders and civil society representatives [at a side event of the G20 Health Ministers Meeting to launch the report](#).

Strong support by G20 governments, international partners, NGOs and civil society on findings of report, urgent need to take solutions forward and commitments to contribute to these efforts

WHO Director-General Dr Tedros Ghebreyesus and Minister of Health of South Africa Dr Aaron Motaledi have also released an [op-ed in the *Lancet Infectious Diseases*](#) highlighting the importance of this milestone towards accelerating progress to end TB.

“ The meeting in Limpopo marks an important first step, providing an opportunity to align on principles and **pathways for equitable pricing, sustainable financing, and country delivery plans**.

Working alongside the Accelerator Council's Finance and Access Working Group, G20 members, invited countries, industry, funders, and civil society can ensure that new tuberculosis vaccines, once proven safe and effective, are **introduced quickly and fairly, where public health need is greatest**. ”

Tedros Adhanom Ghebreyesus
Director General, World Health Organization;
Co-convener, F&A WG

Honorable Minister of Health Dr. Aaron Motsoaledi
Minister of Health, Republic of South Africa;
Co-convener, F&A WG

The report provides a comprehensive view on novel TB vaccine finance & access

Contents

Foreword	vi	2.4.2 Objectives	16
Acknowledgements	viii	2.4.3 Methodology	16
Abbreviations	ix	2.4.4 Results overview	17
Executive summary	xi	2.4.5 Comparison of demand and supply projections	18
01 Introduction	1	2.4.6 Results overview	18
1.1 Background	1	2.4.7 Key findings from comparison of demand and supply projection	19
1.2 A vision for equitable access to novel TB vaccines	1	2.4.8 Key takeaways from comparison of demand and supply projections	19
02 Landscape and evidence to date	3	2.5 Financing landscape	20
2.1 Country access and financing plans	4	2.5.1 Introduction	20
2.1.1 Introduction	4	2.5.2 Objectives	20
2.1.2 Objectives	4	2.5.3 Key findings from financing landscape	20
2.1.3 Key findings from country consultations	4	2.5.4 Key takeaways from financing landscape	23
2.1.4 Key takeaways from country consultations	6	03 Solutions and roadmap	24
2.2 Demand projections	8	3.1 Summary of key identified gaps	24
2.2.1 Introduction	8	3.2 Proposed solutions and mechanisms	26
2.2.2 Objectives	8	3.3 Call to action	32
2.2.3 Methodology	8	3.4 Next steps	32
2.2.4 Results overview	8	References	33
2.2.5 Key findings from demand projections	10	Annexes	35
2.2.6 Key takeaways from demand projections	11	Purpose of this annex	36
2.3 Product licensing and access strategies	11	Annex 1 Country access and financing plans	36
2.3.1 Introduction	11	Annex 2 Demand projections	37
2.3.2 Objectives	13	Annex 3 Product licensing and access strategies	41
2.3.3 Key findings from supply stakeholder consultations	13	Annex 4 Supply projections and comparison against demand	43
2.3.4 Key takeaways from supply stakeholder consultations	15	Annex 5 Financing Landscape	47
2.4 Supply projections and comparison against demand	16	Annex 6 Financing gap modelling	50
2.4.1 Introduction	16	Annex 7 List of mechanisms	53

Foreword

Tuberculosis (TB) is one of the world's deadliest infectious diseases. Despite global commitments to end TB by 2030, progress is fragile. Every year, more than 10 million people fall sick with TB and more than one million people die from the disease, mostly in low- and middle-income countries.

Global efforts to combat TB have saved an estimated 79 million lives between 2000 and 2023. However, drastic cuts in health financing, rising drug resistance and disruptions to health services due to conflicts, natural disasters and other shocks threaten this progress.

The World Health Organization (WHO) is committed to supporting science to find new solutions to fight TB. More than a century after the introduction of BCG, the only licensed TB vaccine, promising novel TB vaccine candidates have reached late stage development, offering the potential to alter the trajectory of the global TB epidemic.

WHO estimates that, over 25 years, a vaccine for adolescents and adults that is 50% effective could avert up to 76 million TB cases, 8.5 million deaths, 42 million courses of antibiotics and up to US\$42 billion in costs faced by households affected by TB affected, especially for the poorest and most vulnerable (1).

In 2023, WHO established the TB Vaccine Accelerator Council to facilitate the development, testing, authorization, and use of new TB vaccines. The Council convenes governments, partners,

Dr Tedros Adhanom Ghebreyesus
Director-General, WHO



South Africa is a proud member of the TB Vaccine Accelerator and co-convenor of the F&A WG. The Working Group brings together a remarkable assembly of expertise, commitment and shared purpose, reflecting the urgency and scale of the challenge before us, and the extraordinary opportunity we have to transform the future of TB prevention and control

Dr Aaron Motsoaledi
Minister of Health, Republic of South Africa;
Co-convenor, F&A WG



financing institutions, and civil society to coordinate global efforts across the vaccine value chain, from research and development through manufacturing and regulatory readiness to financing, procurement and country introductions. The TB Vaccine Accelerator provides a platform for collaboration to ensure that the next generation of TB vaccines translates rapidly into public health impact.

We know from prior experience that finance and access considerations are critical to accelerate vaccine rollout. As the science moves forward, pathways for ensuring equity and access must be included in early plans for manufacturing. In addition, ensuring sustainable financing for procurement and supporting the evolution of healthy TB vaccine markets will be vital for maximizing the speed and impact of introduction.

This report represents one of the first outputs of the TB Vaccine Accelerator's Finance and Access Working Group, reflecting insights from the group itself, as well as from high-burden countries and public and private partners. The report provides an analysis, with concrete solutions for how to prepare for country access to and financing of new vaccines.

New TB vaccines have the potential to save millions of lives faster and change the course of the epidemic. By harnessing the power of science, partnership and finance, we can realize our shared vision to end TB.

globally in a way that is sustainable, equitable and impactful. We are firmly committed to ending TB and have long been at the forefront of the global fight against TB, including hosting multiple clinical trial sites for promising TB vaccine candidates. As a result, we are now proactively preparing for TB vaccine candidates that are still in clinical trials.

The TB Vaccine Accelerator is a vital tool to ensure equitable access to novel TB vaccines, and Gavi, the Vaccine Alliance, is honored to play our part. As co-convenor of the TB Vaccine Accelerator F&A WG, we bring decades of experience in vaccine market shaping and financing. In 2024, Gavi added novel TB vaccines to our vaccine portfolio, enabling us to accelerate

Dr Sania Nishtar
Chief Executive Officer, Gavi, the Vaccine Alliance; Co-convenor, F&A WG



Brazil strongly supports the WHO TB Vaccine Accelerator Council and the F&A WG, which aims to catalyze innovative and sustainable solutions for equitable global access and financing of novel TB vaccines for adults and adolescents. This multilateral effort reflects the shared understanding that science and solidarity must go hand in hand to achieve global health equity. The Government of Brazil considers the elimination of TB as a public health problem a national

Dr Alexandre Padilha
Minister of Health, Brazil; Co-chair, TB Vaccine Accelerator Council



As one of the countries with the highest TB burden, ensuring the availability of a novel TB vaccine is a national priority for Indonesia. The country stands ready to lead global efforts to accelerate the development and deployment of a new TB vaccine through strong political commitment, regional

Budi Gunadi Sadikin
Minister of Health, Indonesia; Co-chair, TB Vaccine Accelerator Council



our work to develop market shaping and financing strategies for low-income and middle-income countries. That work will continue throughout 2026 and beyond, as we work with WHO and other partners to unlock the potential of novel TB vaccines for all who can benefit.

priority, which the Brazilian research and innovation ecosystem stands ready to respond to. Brazil believes that with advance planning, strategic investments, and strong partnerships, effective implementation of new technologies is achievable. Brazil remains firmly committed to international cooperation, scientific advancement, and equitable access, calling upon global partners to join us in transforming the promise of a new TB vaccine into a reality for all.

collaboration and strategic investment in research and manufacturing capacity. Indonesia is demonstrating concrete leadership toward equitable access, turning innovation into availability and advancing the shared goal of ending TB worldwide.

The F&A WG proposes six interlinked solutions in the report

Accelerating equitable access to novel TB vaccines will require **early, coordinated and transparent global action.**



SOLUTION 1

Global catalytic instrument(s) that assure(s) funded demand from countries and donors to incentivize manufacturers to expand capacity and negotiate more affordable price(s).



SOLUTION 4

Coordination platform for supply and demand stakeholders to align, supported by shared roadmaps and regular dialogue that can help synchronize timelines between manufacturing, financing and country access.



SOLUTION 2

Systematic and early generation of country-led evidence packages including demand forecasts, cost-effectiveness analyses and budget impact studies that enable governments to make timely and informed decisions.



SOLUTION 5

Sharing of key information that is important for equitable access and is not commercially sensitive, to support country planning and trust building through market transparency.



SOLUTION 3

Clarity on available domestic financing commitments and external support, supported by scenario modelling¹, that can help identify gaps and mobilize resources.



SOLUTION 6

Advocacy for licensing and technology transfer to at least one manufacturer in each high-burden region that can help strengthen supply security, regional ownership and vaccine acceptance.

Solution 1: Global catalytic instrument(s) to guarantee demand which will boost supply and drive down prices

Description

Instrument(s) to aggregate demand for high-burden MICs and LICs to provide visibility into aggregated demand from multiple countries, as well as to aggregate financing to de-risk supplier investments and facilitate access and price commitments from suppliers.

This could directly address multiple gaps such as de-risking manufacturing investments, creating production at scale to lower vaccine costs and providing governments with more affordable and predictable supply.

The instrument(s) thus provides a platform not only for demand aggregation but also to incentivize resources pooling between MICs, LICs and donor partners, strengthening collective buying power and reinforcing equity. The instrument(s) also support global coordination between actors involved in supply and demand to minimize delays and help ensure risk is shared between manufacturers, donors and countries, and to maximize public health impact.

Framed as catalytic and time-bound, it should be designed to incentivize early supply availability and to evolve as the market matures. The structure of the global instrument could comprise complementary parameters (see below).

Why is this needed?

- Lack of predictable, concrete and long-term demand signals, combined with the absence of reliable financing commitments.
- Risk in production capacity scale-up due to reluctance by developers and manufacturers in advance of licensure and recommendations for use potentially leading to supply shortages and inequitable access
- Potential delays in country access, need for allocation mechanisms for the constrained supply, and high initial prices due to production scale-up delays.



Volume guarantees

to provide predictable demand signals and allow manufacturers to invest confidently in scaling up production



Mechanisms based on financing commitments and estimated volumes

accelerate and pull core funding early to demonstrate funded demand to manufacturers and potentially reduce perceived risk on funded demand materialization



Entry incentives for the first two suppliers

to bring vaccines to market, ensuring rapid availability of initial doses.



Price evolution mechanisms

including periodic reviews of cost-of-goods (COGS) and rules for step-down pricing as demand expands, to ensure affordability over time



Sunset and transition criteria

to ensure that, once a competitive and sustainable market is shaped, the instrument(s) does neither creates distortions or dependency, nor locks up the market to early suppliers.



Inclusive country scope

to include all high-burden countries regardless of their procurement and financing channels



LMIC-specific considerations

for access, equity and affordability

Solution 2: Early evidence generation

Description

The solution emphasizes creating country-led evidence packages to accelerate decision-making and budget planning, alongside global policy guidance.

These packages should include demand forecasts, cost-effectiveness analyses, and budget impact estimates, enabling countries to prioritize TB vaccine introduction and secure financing.

In the absence of complete data, scenario planning through modeling can guide early strategies. Technical assistance and tools are needed to build local capacity for evidence generation and engage communities early.

Comprehensive evidence will also support risk assessments for demand and financing, ensuring public health needs translate into funded demand.

Why is this needed?

- Potential lag between product licensure, policy recommendations and country adoption if data is insufficient.
- To generate required country-level evidence e.g. cost-effectiveness, health impact, target populations.
- Potential of clinical trials being focused on narrower populations than their intended use, leaving gaps in data for high-risk groups such as PLHIV, adolescents, occupational cohorts or uninfected populations.
- Reluctance of countries to prioritize TB vaccines over other health interventions, especially in constrained fiscal environments without required evidence.

Solution 3: Clarity on domestic and external funding

Description

A blended financing approach is essential, combining external catalytic funds with domestic financing to secure early commitments from countries and donors.

Early adopter countries should indicate intent to purchase TB vaccines and accelerate budget decisions, while donors clarify funding scope, timing, and eligibility.

Multilateral and regional financiers should complement—not replace—domestic funding and promote co-financing. Scenario modeling is needed to identify funding gaps, using WHO's initial model as a starting point.

Why is this needed?

- Clarify financing gaps and explore innovative mechanisms by assessing available domestic and external funding to enable early actions and accelerated access.
- Provide strong funded demand signals to suppliers to encourage at-risk manufacturing at scale, supporting catalytic instruments for early market shaping.
- Leverage MICs' financing potential to drive the TB vaccine market and promote self-sufficiency, while recognizing domestic budgets may be insufficient for all high-burden countries.
- Balance external and domestic funding to avoid under-capitalization of global instruments and ensure sustainability, reducing vulnerability to volatility and declining external support.

Solution 4: Coordination between demand and supply

Description

A structured coordination platform that links supply- and demand-side stakeholders, including a shared roadmap with clear sequencing of activities, should be developed.

In addition, develop an equitable allocation framework, as has been done for numerous other novel vaccines, in case supply is constrained in the years immediately following licensure,

Regular multi-stakeholder roundtables should be convened to monitor and align expectations regarding access. Coordination should be institutionalized as the backbone of an equitable vaccine access strategy, ensuring that no track operates in isolation and that bottlenecks are addressed early. The F&A WG will aim to serve this purpose in 2026–2027.

Why is this needed?

- Lack of coordination can delay introduction if supply distribution, financing arrangements, procurement processes and country readiness move on misaligned timelines. For novel TB vaccines, such misalignment could delay public health impact once vaccines are successfully licensed. Coordination is therefore essential to align decision-making across all stakeholders. In addition, coordination can promote synergy, alignment and shared accountability in the implementation of key solutions, ensuring a holistic approach to facilitating access to novel TB vaccines.

Solution 5: Market transparency for key access information

Description

Establishing minimum standards for transparency for information that is important for equitable access and is not commercially sensitive is a core aspect of achieving the necessary visibility to achieve access. Suppliers would be requested to disclose such information as it becomes available.

This could include pricing strategies and eventually price corridors, licensing terms including geographic scope and royalty structures, and access and distribution plans for different countries and regions. This approach balances the need for transparency with feasibility, while building trust and accelerating country-level decision-making.

The global instrument(s) in Solution 1 could support in securing commitments from suppliers.

Why is this needed?

- Countries and funders often lack visibility on suppliers' licensing and manufacturing plans (i.e. who will manufacture the product, where will the manufacturing take place and which countries can buy from these manufacturers), and access and pricing strategies (i.e. how will suppliers ensure equitable access to all countries in need, how will they distribute and allocate supply, at what price and to which countries or mechanisms). This information gap can delay national planning, funding availability and create uncertainty for procurement. Information asymmetries can result in inequitable access.

Solution 6: Licensing and technology transfer to at least one manufacturer in each high burden region

Description

Advocacy should focus on securing manufacturing capacity for at least one TB vaccine in each high-burden region—Africa, Asia, and Latin America—through technology transfer and IP-sharing agreements.

Initial steps could involve fill-finish operations, progressing to full-scale manufacturing, supported by credible demand and financing signals and strong regulatory capacity.

Agreements between manufacturers and governments are essential to ensure regional supply and equitable distribution.

Regional manufacturing must align with global supply and demand planning to avoid fragmentation. The ultimate goal is a diversified, resilient global manufacturing base that reduces risks of shortages and inequities.

Why is this needed?

- Regional manufacturing capacity in every high-burden region can help strengthen equitable access, ensure regional supply security and increase acceptability of vaccines. If global supply is constrained, there may be delays in access in countries and regions without manufacturing capacity. Regional manufacturing builds resilience and strengthens political ownership and regional self-sufficiency.

Call to action



Global Organizations

- World Health Organization (WHO) has a central coordinating role in fostering global collaboration and accountability among all stakeholders.



Governments

- High-Burden Country Governments: Translate political will into funded demand via purchasing commitments and ensure early planning and investments for country readiness and vaccine introduction.
- High-Income Countries (HICs): Provide external funding to countries in need and relevant funding agencies.
- G20 Governments: Affirm responsibility and commitment to treat novel TB vaccines as global public goods. Prioritize and safeguard equitable access across all regions.



Civil Society

- Support accountability from governments and global partners.
- Shape demand and promote community engagement for successful rollout.



Supply-Side Stakeholders

- Provide transparency on access plans.
- Invest in manufacturing capacity to meet demand.
- Ensure equitable distribution and affordability for MICs and LICs



Funding & Financing Partners

- Offer external funding and loans to support country-level procurement based on needs and public health impact.



Procurement, Innovative Financing & Market Shaping Partners

- Provide technical expertise for designing and implementing financing instruments.
- Organizations including Gavi, The Global Fund, MedAccess, and PAHO Revolving Fund, among others, may have roles to support financing approaches and instruments for introduction and scaling of novel TB vaccines in low- and middle-income countries.

Next steps

The development and implementation of financing and access strategies by countries is an essential step in the planning and equitable access to new TB vaccines once they become available.

The F&A WG will continue to advance this agenda at a global level. All the members of the F&A WG will continue to actively engage and collaborate with all other key stakeholders (including supply side stakeholders, global funders, civil society and other areas of the TB Vaccine Accelerator).



In 2026–2027, the F&A WG will:

- Prioritize efforts to **develop most urgently needed solutions**, and **additional analyses** needed to support these.
- In the short-term, the F&A WG may need to **target efforts** to support **TB vaccines first coming to market** and **early adopter countries**
- Consider **medium-long term solutions** that may be needed as the vaccines come to market to ensure equitable access to **all countries** and **a healthy and competitive supplier base**
- Ensure that solutions **optimize public health impact**.

We plan to keep engaging civil society in the design and development of the solutions.
Our next civil society webinar will be in 2H of 2026

Remarks from Finance & Access Working Group Co-Convenors

03

Discussion



Questions and perspectives from civil society

04

Closing & Next steps

Thank you

